Literature DB >> 32766831

The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study.

Rinkoo Dalan1, Li Wei Ang2, Wilnard Y T Tan2, Siew-Wai Fong3,4, Woo Chiao Tay2, Yi-Hao Chan3, Laurent Renia3, Lisa F P Ng3, David Chien Lye5, Daniel E K Chew1, Barnaby E Young5.   

Abstract

Entities:  

Keywords:  Angiotensin receptor blocker (ARB); Angiotensin-converting enzyme inhibitor (ACE-I); Diabetes; Dipeptidyl peptidase 4 inhibitor (DPP4i); Hypertension

Year:  2021        PMID： 32766831      PMCID： PMC7454507          DOI： 10.1093/ehjcvp/pvaa098

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  19 in total

Review 1.  Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Authors:  Jordan Loader; Frances C Taylor; Erik Lampa; Johan Sundström
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

2.  Statin use is associated with lower disease severity in COVID-19 infection.

Authors:  Wilnard Y T Tan; Barnaby E Young; David Chien Lye; Daniel E K Chew; Rinkoo Dalan
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

Review 3.  Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.

Authors:  Bao Sun; Shiqiong Huang; Jiecan Zhou
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

4.  Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.

Authors:  Rimesh Pal; Mainak Banerjee; Soham Mukherjee; Ranjitpal Singh Bhogal; Amanpreet Kaur; Sanjay K Bhadada
Journal:  Ther Adv Endocrinol Metab       Date:  2021-02-20       Impact factor: 3.565

5.  Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.

Authors:  B M Bonora; A Avogaro; G P Fadini
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

6.  Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.

Authors:  Simone Bastrup Israelsen; Anton Pottegård; Håkon Sandholdt; Sten Madsbad; Reimar Wernich Thomsen; Thomas Benfield
Journal:  Diabetes Obes Metab       Date:  2021-02-16       Impact factor: 6.408

7.  Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Aristi Boulmpou; Michael Doumas
Journal:  Diabetes Obes Metab       Date:  2021-03-12       Impact factor: 6.408

Review 8.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

Authors:  Soo Lim; Jae Hyun Bae; Hyuk-Sang Kwon; Michael A Nauck
Journal:  Nat Rev Endocrinol       Date:  2020-11-13       Impact factor: 47.564

9.  Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Syed Shahzad Hasan; Chia Siang Kow; Muhammad Abdul Hadi; Syed Tabish Razi Zaidi; Hamid A Merchant
Journal:  Am J Cardiovasc Drugs       Date:  2020-09-12       Impact factor: 3.571

10.  Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Alexandra Katsimardou; Maria Toumpourleka; Michael Doumas
Journal:  Diabetes Ther       Date:  2020-10-14       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.